I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Computed tomography (CT) is the primary imaging mode for planning in radiotherapy (RT). The accuracy of RT depends on many factors, including accurate patient setup during the treatment.\[[@ref1][@ref2][@ref3]\] Positioning uncertainties are the potential source of errors in the radiation therapy that may lead to a dose delivery that is different from the one that was intended to be given originally. For the last few years, the use of image-guided RT (IGRT) tries to reduce the magnitude of uncertainty in patient setup.\[[@ref4]\] There are several imaging modalities used for IGRT, one of which is CT-on-rails.\[[@ref5][@ref6][@ref7]\] CT-on-rails gives a complete three-dimensional representation of patient anatomy and enables accurate internal organ delineation and patient setup corrections. Variations in dose delivery stem from setup errors, internal organ motion, and deformation, which can contribute to underdosage of the tumor or overdosage of normal tissue. Those variations may potentially be related to a reduction of local tumor control and an increase of side effects.

Dose--volume histograms (DVHs), minimum, maximum, and mean doses, as well as isodose distribution review on the axial slices are the tools that are mainly used in RT plan evaluation. These tools do not take into account the radiobiological characteristics of the organs at risk (OAR) and tumors. Radiobiological measures that have been proposed in the treatment plan evaluation are the biologically effective uniform dose (BEUD) (![](JMP-43-28-g001.jpg)) and the complication-free tumor control probability (*P*~+~).\[[@ref8][@ref9]\] ![](JMP-43-28-g001.jpg) is a concept that assumes equivalency of the different dose distributions when they are causing the same probability of tumor control or normal tissue complication.\[[@ref10]\]

The goal of the study is to evaluate the expected clinical impact of dose delivery when setup corrections are taken into account.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Ten head-and-neck cancer patients with different tumor locations and sizes were selected for this study. Optimal plans were calculated for the patients' treatment based on their planning CT, and CT-on-rail images were taken in each fraction before the treatment. Three sets of dose distributions were calculated for each patient and compared based on several dosimetric and radiobiological parameters.\[[@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\]

Treatment planning and computed tomography-on-rails acquisition {#sec2-1}
---------------------------------------------------------------

Patients' baseline planning was performed on the ADAC Pinnacle Treatment Planning System. An in-room image-guided system with CT-on-rails was used for the daily setup imaging and corrections CT-on-rails system (EXaCT, Varian Oncology Systems, Palo Alto, CA, USA). The online correction was performed before each treatment, to align target volumes. For each fraction, CT-on-rails image sets were taken and the original IMRT contours were overlaid on each daily CT set to acquire and verify the couch corrections needed for the setup adjustments. CT sets taken for each fraction were then used for further analysis. For the "cascade" case, the planning CT was applied to the 1^st^ day of treatment CT-on-rails image set and that way we got the 1^st^-day results. Then, the 1^st^-day results were applied to the 2^nd^-day CT-on-rails image set, the 2^nd^-day results to the 3^rd^ day, etc. final deformation was then used for the comparison with the planned data. In the "one-to-all" case, the planning CT was applied to all of the CT-on-rail image sets of each patient and the final set was used for further analysis and comparison.

This study evaluates treatment plans based on the expected effect of the patient setup correction (done on the basis of the everyday CT-on-rails) on the dose distribution and plan parameters.

Different sensitive OAR was evaluated for each patient case depending on the area of the treatment \[[Table 1](#T1){ref-type="table"}\].

###### 

Sensitive organs at risks evaluated per patient

![](JMP-43-28-g002)

Data registration {#sec2-2}
-----------------

In this study, each patient had a reference kilovoltage CT taken that was then used for the development of the treatment plan; this CT is referred to as planning CT. The planning CT images that were exported from the treatment planning system with the corresponding plan dose and structures, for the ten chosen head-and-neck cancer patients, were imported into the Velocity AI (Velocity AI, Velocity Medical Solutions, Atlanta, GA, USA)\[[@ref16]\] through the DICOM RT protocol.\[[@ref17][@ref18]\] DICOM registration was used to register dose data to the plan CT. For the selected previously delineated and imported structures, DVH data were exported. Next final transformation of the CT-on-rails data set for each of the two studied approaches was imported and registered to the planning CT. CT-on-rails resampled dose data were then registered to the planning CT. For the same previously selected structures, DVHs were calculated and exported. DVH files were then multiplied by the correct number of fractions to get the total dose for each patient \[[Table 2](#T2){ref-type="table"}\].

###### 

Prescription values per patient

![](JMP-43-28-g003)

Dosimetric and radiobiological treatment plan evaluation {#sec2-3}
--------------------------------------------------------

For the dosimetric evaluation of the treatment plan, DVHs are routinely used together with the mean dose of the dose distribution to the tumor planning target volume (PTV) and tolerance doses of the various tissues. Tolerance doses are usually given as the length of the irradiated portion of structure or fraction (volume) of the organ treated. These data are derived from patient observations and follow the conventional fraction schedule.\[[@ref19][@ref20]\] The dose constraints that were used for plan optimization in our study are given in [Table 3](#T3){ref-type="table"}.

###### 

Dose constraints for plan optimization for the various head-and-neck structures used for plan comparison

![](JMP-43-28-g004)

In this study, linear-quadratic-Poisson model is used to describe the dose--response relations of the tumors and normal tissues:

![](JMP-43-28-g005.jpg)

where *P*(*D*) is the probability to control the tumor or induce a certain injury to a normal tissue that is irradiated uniformly with a dose *D*. *D*~50~ is the dose which gives a 50% response, and *γ* is the maximum normalized dose--response gradient. Parameters *D*~50~ and *γ* are organ and type of clinical endpoint specific and can be derived directly from clinical data.\[[@ref12][@ref13][@ref14]\] The response of a normal tissue to a nonuniform dose distribution is given by the relative seriality model which accounts for the volume effect. The dose--response parameters that were used in this study are based on the published data and presented in [Table 4](#T4){ref-type="table"}.\[[@ref21]\] This study is assuming that the 10 patients are of average radiosensitivity, thus characterized by the mean estimates of the radiobiological parameters presented.

###### 

Summary of the model parameter values used. The α/β was assumed to be 3 Gy for normal tissues and 10 Gy for the targets

![](JMP-43-28-g006)

Theory for applied methodology {#sec2-4}
------------------------------

Dosimetric evaluation does not take into account the biological characteristics of the tumor. Different solutions to this problem have been recommended.\[[@ref22][@ref23][@ref24]\] The article by Mavroidis *et al*.\[[@ref10]\] generalized the mathematical expressions of *D*~eff~\[[@ref25]\] and EUD\[[@ref26]\] to deal with multiple target or normal tissue cases and introduced the BEUD concept. This is the dose that causes the same tumor control or normal tissue complication probability as the real dose distribution. This allows for the comparison of treatment plans based on the radiobiological endpoints by normalizing dose distributions to a common prescription point and plotting the tissue response probability versus ![](JMP-43-28-g001.jpg), which is given from the following analytical formula:

![](JMP-43-28-g007.jpg)

The scalar quantity *P*~+~, which expresses the probability of achieving tumor control without causing severe damage to normal tissue, can be estimated from the following mathematical expression:\[[@ref8]\]

![](JMP-43-28-g008.jpg)

where *P*~B~ is the probability of getting benefit from treatment (tumor control) and *P*~I~ is the probability of causing severe injury to normal tissues (complications).

Statistical analysis

The different dose distributions of the study were radiobiologically evaluated using the radiation sensitivities of the tumors and OARs involved to calculate the probabilities of benefit and injury, as well as the values of complication-free tumor control probability *P*~+~ and ![](JMP-43-28-g001.jpg).

Statistical analysis is done for *P*~+~ clinical delivered values for the three cases -- one-to-all, cascade, and planed values. Nonparametric statistical tests were used since they have no assumptions regarding distribution of underlying populations or variance. In view of the fact that our sample size is rather small (*n* = 10), several nonparametric tests for small samples were performed on the calculated data:

The Mann--Whitney U-testThe sign testThe Wilcoxon signed-rank testThe Kendall tau rank correlation coefficient.

The Mann--Whitney U-test is used to decide whether or not there is a difference between the two groups. The groups compared were one-to-all versus planned values, cascade versus planned values, and one-to-all versus cascade values. The sign test was used to determine whether planned and CT-on-rails calculated data are different. The most accurate nonparametric test for paired data is the Wilcoxon signed-rank test. With this test, we test our null hypothesis that when it comes to calculated *P*~+~ values, CT-on-rails data will produce worse results than the planned data. The Kendall tau rank correlation coefficient is used for nonparametric data and is used to measure the degree of correspondence between sets of rankings where the measures are not equidistant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Graphical evaluation of the different plans {#sec2-5}
-------------------------------------------

In [Figure 1](#F1){ref-type="fig"} (patient 9 example) and in Appendix Figures [1](#F2){ref-type="fig"} and [2](#F3){ref-type="fig"}, the treatment plans are compared in terms of the DVH and BEUD of benefit (![](JMP-43-28-g009.jpg)). The dose--response curves of each target and OAR, together with the corresponding *P*~+~ curves, are presented for the individual patients and plans. The dose--response curves are normalized to the ![](JMP-43-28-g009.jpg), which is forcing the response curves of the PTV (*P*~B~) of the evaluated cases to coincide.

![The curves derived from the radiobiological evaluation of the dose distributions are plotted, with the on the ![](JMP-43-28-g009.jpg) dose axis. The solid line indicates the planned dose distribution, while the dashed line refers to the one-to-all case and the dotted line to the cascade case. These results correspond to patient 9](JMP-43-28-g010){#F1}

![The dose--volume histograms of the planning target volume and the organs at risk are illustrated. The solid lines indicate the planned dose distributions, while the dashed lines correspond to the one-to-all case and the dotted lines to the cascade case](JMP-43-28-g011){#F2}

![The curves derived from the radiobiological evaluation of the dose distributions are plotted using the ![](JMP-43-28-g009.jpg) as the unit on the dose axis. The solid lines indicate the planned dose distributions, while the dashed lines correspond to the one-to-all case and the dotted lines to the cascade case](JMP-43-28-g012){#F3}

In Appendix Figures [1](#F2){ref-type="fig"} and [2](#F3){ref-type="fig"}, more qualitative description of the comparison is presented. For most of the cases, it is shown that the treatment plan is satisfying plan objectives. In most cases, OAR is spared very well apart from a few that are located close to the PTV, left parotid for patient 1, larynx for patient 2, right parotid for patient 3, mandible for patients 4 and 5, left optic nerve for patient 6, right parotid for patient 7, optic chiasm for patient 9, and optic nerves for patient 10.

Overall, the cascade case, when it comes to the PTV coverage, followed the plan values more closely than the one-to-all case, which is also visible from the plots in Appendix Figures [1](#F2){ref-type="fig"} and [2](#F3){ref-type="fig"}. Plotting the curves of *P*~B~, *P*~I~, and *P*~+~ of the three cases (plan, one-to-all, and cascade) on the same diagram shows that the corresponding curves of the PTVs (*P*~B~) for the three cases coincide. In this situation, the response curves of the OAR (*P*~I~) determine the difference in the plans that are compared, i.e., which case is superior from the radiobiological point of view. In these plots, *P*~+~ is also used as an objective that depicts the quality of the cases being compared.

Quantitative summary of the dosimetric and radiobiological metrics {#sec2-6}
------------------------------------------------------------------

The values obtained for structures based on their tolerance doses \[[Table 3](#T3){ref-type="table"}\] are listed in [Appendix Table 1](#T5){ref-type="table"}. Based on those values, the differences between the planned and case values were calculated. In Appendix Tables [1](#T5){ref-type="table"}--[3](#T7){ref-type="table"}, the quantitative summary of the physical and biological comparisons is presented. The values (per patient and case) that represent the highest *P*~+~ and the lowest *P*~I~ are highlighted in bold.

###### 

Dosimetric value differences per patient per case (each case compared to planed values)

![](JMP-43-28-g013)

###### 

Summary of the radiobiological comparison for the ten patients

![](JMP-43-28-g014)

###### 

Quantitative summary of the biological comparison for the dose distributions of the ten cases

![](JMP-43-28-g015)

[Table 5](#T8){ref-type="table"} lists the differences in *P*~B~, *P*~I~, and *P*~+~ between each case and the planned values. The higher the value of the *P*~I~ difference, the higher is the *P*~I~ for the particular case (same goes for the *P*~+~ and *P*~B~ comparison). The cascade case shows higher *P*~I~ values in 70% of the cases compared to the one-to-all case. The *P*~I~ plan values are lower than either of the cases in three patients out of ten.

###### 

*P* values comparison (difference) of the "clinical" values between the two cases and the planned values

![](JMP-43-28-g016)

The dose variations in the PTV are listed in [Table 6](#T9){ref-type="table"}. The average percentage differences in minimum values were 3.23% and 3.11% for the one-to-all versus plan and cascade versus plan cases, respectively, and 0.49% and 0.57% in the maximum values, respectively.

###### 

Planning target volume dose variations per patient (Gy) with the deviations of the two cases from the plan

![](JMP-43-28-g017)

For both analyzed cases, PTV coverage at the prescription dose and mean/maximum doses to the OAR are the same or slightly worse than it was in the plan \[[Appendix Table 1](#T5){ref-type="table"}\]. Average difference for the dosimetric values comparison of the "one-to-all" case to the planned values is 0.6 ± 1.8 Gy and for the "cascade" case to plan is 0.5 ± 1.8 Gy. When the patients are grouped in three groups based on the tumor location, the variation is 0.2 ± 0.4 Gy for both the "one-to-all" and "cascade" cases for the first group, 1.3 ± 3.3 Gy and 1.2 ± 3.4 Gy for the second group, respectively, and 0.2 ± 0.3 Gy for the third group, respectively. [Table 6](#T9){ref-type="table"} shows that plans are not very homogeneous with some of the homogeneity actually improving with the one-to-all or cascade cases.

In [Appendix Table 2](#T6){ref-type="table"}, the clinical column indicates the biological effect calculated based on the prescribed dose delivered in the cases compared. The optimal column shows the corresponding highest achievable *P*~+~ after dose escalation. Since the probability of achieving tumor control without causing severe damage to normal tissues is the pure benefit from the treatment (tumor control probability − normal tissue complication probability), in the case where the values of *P*~B~ are comparable, *P*~+~ is going to be lower mainly due to the higher *P*~I~. For the 10 patients, *P*~+~ is lowest for the cascade case in the clinical column (in the 80% of cases total). Clinical standard for the overall *P*~I~ is usually set at 5%. Only for one patient, patient 4, *P*~I~ is at this acceptable level. Overall, the lowest *P*~I~ is present in the one-to-all cases. Higher overall *P*~I~ for the rest of cases stems from the significantly higher *P*(*D*) of the OAR for those cases, i.e., left parotid at 27.24% for cascade case versus 16.91% for the one-to-all case (patient 2), right parotid at 60.40% for the plan versus 55.61% for the one-to-all-case (patient 5), left eye at 37.28% for cascade case versus 33.57 for the one-to-all case (patient 6), brainstem at 5.79% for the plan versus 4.81% for the one-to-all case (patient 7), and left orbit at 7.40% for the plan versus 6.96% for the one-to-all case (patient 8). The *P*(*D*) of the other OARs is also higher in either cascade or plan cases versus the one-to-all case, contributing to the higher *P*~I~ in those cases.

Statistical analysis {#sec2-7}
--------------------

The Mann--Whitney U-test was performed with a 95% degree of uncertainty (α = 0.05). The result is significant if calculated \| Z score\| \> \|Z critical\|. For all three examined group pairs, \|Z score\| = 0.076. Since for the two-tailed test, \|Z critical\| = 1.960, and for one-tailed test, \|Z critical\| = 1.645, it is obvious that, in our case, the result is not statistically significant, and we cannot state with 95% certainty that there is a difference between the two groups for either a one-tailed test or a two-tailed test.

For the sign test, the result is significant if *P* \< α. The 95% certainty required α = 0.05. For the comparison between the one-to-all and planned data, the calculated *P* is 0.344, and between the cascade and planned data, *P* = 1.246. This test showed that the result is not significant, and we can state that there is no difference between the planned and the CT-on-rails *P*~+~ values.

In the Wilcoxon signed-rank test, the critical value of W for *n* = 10 and for a one-tailed test in which alpha = 0.05 equals 11. The null hypothesis can be rejected if test statistics W is greater than or equal to W critical. In our case, when the one-to-all data were compared with the planned data statistics, W was 25, and for the cascade versus planned data comparison, W was 31. Given that the test statistics W is greater than the critical W for both cases, null hypothesis is rejected, i.e., dosimetrically (at least when comparing *P*~+~ values), CT-on-rails data are not worse or better than the planned data.

The calculated Kendall tau rank correlation coefficient value for the one-to-all versus planned data was 0.911, for the cascade versus planned data was 0.867, and for the one-to-all versus cascade data was 0.956. High tau values indicate high degree of correspondence between the each group\'s rankings.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In the physical analysis of the different dose distributions, criteria such as the mean and minimum target doses, mean and maximum normal tissue doses, isodose levels, and DVHs are mostly used.\[[@ref27][@ref28]\] The plans tried to achieve adequate PTV coverage while respecting the tolerance doses of the involved OAR. However, when comparing different dose distributions, the differences that are observed on the DVHs and isodose lines are not always reflected in the radiobiological evaluation. This is due to the fact that radiobiological evaluation is more sensitive to small changes in dose distribution that may often not be observed in the DVH-based evaluations.

The expected complication-free tumor control for the "planned," "one-to-all," and "cascade" dose distributions varies from case to case. For most of the studied cases, the planned dose distribution is better than the delivered dose distributions against either the one-to-all or cascade cases. The reason for this is the more effective irradiation of the PTV in the treatment plan, while normal tissue sparing is similar between the three compared distributions. However, even though in some cases the planned dose distribution may deliver lower mean doses to a given OAR, it may also show higher complication probability because of the greater maximum doses and higher seriality value of that OAR (e.g., spinal cord). Furthermore, the expected complication-free tumor control for the planned dose distributions is not always better than the delivered dose distributions for either cascade or one-to-all cases. The reason is that the different plans were not optimized using radiobiological objectives, which means that the planned dose distributions do not correspond to the maximum expected complication-free tumor control. It is observed that for normal tissues, the classification of the different dose distributions over the different cases seems to be more sensitive. In all the cases, the PTV is irradiated almost iso-effectively by the delivered dose distributions in one-to-all and the cascade cases. This is supported by the tumor control probabilities, *P*~B~. On the other hand, the setup uncertainties produce higher normal tissue complications when the OARs move into the high-dose region (patients 3, 5, 6, and 8) or lower expected responses when the OARs move away from the high-dose region (patients 1, 2, 4, 7, 9, and 10).

The findings of this study indicate that for a fraction of the patients, the difference in expected outcome between the delivered against the planned doses can vary from 5% to 10%. For individual OARs, those values are even larger (up to 21%) \[Appendix Table 3\]. These results are in line with a recent study, which utilized head-and-neck cancer patients with daily CT-on-rails, where they report that, without altering patient setup, DVH analysis showed an increase in dose of 3%, 12%, and 16% to the tumor, cord, and parotids, respectively. With patient shifts to correct for setup errors, accurate dose delivery to the tumor was achieved. However, even with shifts, the cord and parotids were still overdosed by 10%.\[[@ref29]\] Another study, using the IGRT results of five head-and-neck patients, reported that the impact of residual setup error, tumor shrinkage, organ deformation, or patient weight loss would result in a considerable change (up to 20%) in the dose received by the OARs.\[[@ref30]\]

The statistical analysis of the *P*~+~ values was done by means of various statistical tests, which showed that there is no statistically significant difference between the planned and the CT-on-rails *P*~+~ values. This confirms the belief that if appropriate setup corrections are done on the patient, before each treatment, the delivered dose distribution is comparable to the planned dose distribution, regardless of how the CT-on-rail data from every fraction are grouped and analyzed.

It has to be stated that the determination of the model parameters expressing the effective radiosensitivity of the tissues is subject to uncertainties imposed by the inaccuracies in the patient setup during RT, lack of knowledge of the inter-patient and intra-patient radiosensitivity, and inconsistencies in treatment methodology. Consequently, the determined model parameters (such as the *D*~50~, *γ*, and s) and the corresponding dose--response curves are characterized by confidence intervals. In the present study, most of the tissue response parameters have been taken from recently published clinical studies.\[[@ref12][@ref14][@ref15]\]

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

In this study, the clinical effectiveness of planned and delivered dose distributions of IMRT treatments for head-and-neck cancer was evaluated using both physical and biological criteria. The difference between the "one-to-all" and "cascade" dose distributions was small, statistically insignificant, and very close to the values of the corresponding treatment plans. However, for a fraction of the patients and given OAR, the differences between the delivered and planned doses were particularly large. These findings support the necessity of the accurate patient setup before the treatment using IGRT, thus minimizing dose delivery errors.
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